129 related articles for article (PubMed ID: 15486448)
1. Optimising anaemia management with epoetin beta.
Reed N; Morère JF
Oncology; 2004; 67 Suppl 1():12-6. PubMed ID: 15486448
[TBL] [Abstract][Full Text] [Related]
2. Evolving treatment strategies for anaemia in cancer: experience with epoetin beta.
Aapro M; San Miguel J
Oncology; 2004; 67 Suppl 1():17-22. PubMed ID: 15486449
[TBL] [Abstract][Full Text] [Related]
3. Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetins.
Pujade-Lauraine E; Topham C
Oncology; 2005; 68(2-3):122-9. PubMed ID: 16015034
[TBL] [Abstract][Full Text] [Related]
4. Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study.
Heras P; Kritikos K; Hatzopoulos A; Mitsibounas D
Eur J Cancer Care (Engl); 2008 Nov; 17(6):619-23. PubMed ID: 18707619
[TBL] [Abstract][Full Text] [Related]
5. Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon).
Glaspy J; Beguin Y
Oncology; 2005; 69 Suppl 2():8-16. PubMed ID: 16244505
[TBL] [Abstract][Full Text] [Related]
6. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
7. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
[TBL] [Abstract][Full Text] [Related]
8. Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.
Cortesi E; Gascón P; Henry D; Littlewood T; Milroy R; Pronzato P; Reinhardt U; Shasha D; Thatcher N; Wilkinson P
Oncology; 2005; 68 Suppl 1():22-32. PubMed ID: 15855813
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
11. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
12. Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy.
Suzuki Y; Tokuda Y; Fujiwara Y; Minami H; Ohashi Y; Saijo N
Jpn J Clin Oncol; 2008 Mar; 38(3):214-21. PubMed ID: 18296425
[TBL] [Abstract][Full Text] [Related]
13. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
Henry DH
Drugs; 2007; 67(2):175-94. PubMed ID: 17284083
[TBL] [Abstract][Full Text] [Related]
14. Epoetin Beta once-weekly therapy in anemic patients with solid tumors and non-myeloid hematological malignancies receiving chemotherapy.
Spaëth D; Desablens B; Rodon P; Mennecier B; Oudard S; Moullet I; Ghomari K; Bergougnoux L; Bleuzen P; Jenabian A; Ifrah N
Oncology; 2008; 74(1-2):112-8. PubMed ID: 18547966
[TBL] [Abstract][Full Text] [Related]
15. Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients.
Grossman HA; Goon B; Bowers P; Leitz G;
J Acquir Immune Defic Syndr; 2003 Dec; 34(4):368-78. PubMed ID: 14615654
[TBL] [Abstract][Full Text] [Related]
16. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer.
Steensma DP; Molina R; Sloan JA; Nikcevich DA; Schaefer PL; Rowland KM; Dentchev T; Novotny PJ; Tschetter LK; Alberts SR; Hogan TF; Law A; Loprinzi CL
J Clin Oncol; 2006 Mar; 24(7):1079-89. PubMed ID: 16505427
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment.
Corapcioglu F; Aksu G; Basar EZ; Demirel A; Oncel S; Mutlu A
Pediatr Hematol Oncol; 2008 Sep; 25(6):509-21. PubMed ID: 18728970
[TBL] [Abstract][Full Text] [Related]
18. Treatment of cancer-related anemia with epoetin alfa: a review.
Ferrario E; Ferrari L; Bidoli P; De Candis D; Del Vecchio M; De Dosso S; Buzzoni R; Bajetta E
Cancer Treat Rev; 2004 Oct; 30(6):563-75. PubMed ID: 15325036
[TBL] [Abstract][Full Text] [Related]
19. Once-weekly epoetin beta (30,000 IU) in anemic patients with lung cancer receiving chemotherapy.
Pirker R; Lehnert M; Minar W
Lung Cancer; 2007 Jan; 55(1):89-94. PubMed ID: 17084484
[TBL] [Abstract][Full Text] [Related]
20. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
Biesma B; van de Werf PR; Melissant CF; Brok RG
Lung Cancer; 2007 Oct; 58(1):104-11. PubMed ID: 17601632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
